Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Debiopharm honors cancer research in Lausanne

11.10.2006
The first Debiopharm Life Sciences Award will be presented to Spanish researcher Dr. Eduard Batlle during the 6th annual ISREC cancer research conference in Lausanne, Switzerland. This young scientist and his institute will receive 100,000 francs for his outstanding contributions to cancer research.

The award will be presented Wednesday, October 11, as part of the conference co-organized by EPFL (Ecole Polytechnique Federale deLausanne) and ISREC (Swiss Institute for Experimental Cancer Research) and held on the EPFL campus.

With one foot firmly in fundamental research and the other in clinical work, Eduard Batlle has concentrated his efforts over the past decade on elucidating the mechanisms underlying the onset and progression of colorectal cancer. His independent research in three different areas of colorectal cancer – the study of intestinal stem cells and their malignant counterparts, identification of molecules that prevent malignancy of colorectal tumors, and identification of the genetic components involved in the spread of cancer cells to the liver -- represents an important contribution to our understanding of this deadly cancer. His published articles have been cited more than a thousand times, appearing in journals such as Nature, Nature Cell Biology and Cell. He is also the holder of a patent that is currently being commercially developed by two companies.

Since 2004, Eduard Batlle has led the oncology group at Barcelona’s Biomedical Research Institute (IRB) and is a professor in the Catalan Institute for Research and Advanced Studies. He held postdoctoral research positions in Germany at the University of Marburg and in the Hubrecht Laboratory of the Netherlands Institute for Developmental Biology. He specializes in the areas of molecular biology and colorectal cancer.

POTENTIAL FOR THERAPY

The purpose of the Debiopharm Life Sciences Award is to mentor and motivate innovative European life sciences researchers under the age of 40; this year, the prize is awarded for cancer research. The research must demonstrate innovative vision and originality and have high potential for therapeutic and commercial applications. The jury was composed of three representatives of Debiopharm including Rolland-Yves Mauvernay, the company’s President and Founder; three EPFL professors, including EPFL President Patrick Aebischer; and two external experts. The jury expressed admiration for the « extremely high level » of the candidates.

The Lausanne-based company Debiopharm, founded in 1979, is an independent drug-development company specializing in oncology and serious medical conditions. The company works closely with universities, research institutions, biotech firms or pharmaceutical companies to identify compounds with promising in-vivo results that could lead to new pharmaceutical products. With its considerable expertise and proven track record, Debiopharm shepherds potential products all the way through to the treatment phase. The company is known in particular for having several products such as Eloxatin®, treatment of choice for colorectal cancer, and Decapeptyl® and Trelstar® for prostate cancer treatment. These products are commercialized by pharmaceutical companies such as sanofi-aventis and Watson Pharmaceuticals, Inc.

- For additional information, contact: Dietrich Reinhard, EPFL School of Life Sciences; tel: 021 693 16 43, e-mail: dietrich.reinhard@epfl.ch

- The official presentation ceremony will take place October 11 at 6 :45 pm at EPFL in room SG1, in the presence of Rolland-Yves Mauvernay, Founder and President of Debiopharm and Patrick Aebischer, President of EPFL.

Mary Parlange | alfa
Further information:
http://www.epfl.ch

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>